Experts In Vasectomy and Urological Treatments

Dr. Snoy is a general urologist. In addition to vasectomies he also treats:
• Bladder control
• Overactive bladder
• Bladder cancer
• Urinary incontinence
• Kidney stones
• Prostate disorders
• Prostate cancer
• Erectile dysfunction

Clinical Trials Overview


Urology Group of New Mexico participates in Phase II – IV studies. We have performed clinical studies on prostate, renal, and bladder cancer, BPH, incontinence, overactive bladder, prostatitis, premature ejaculation, erectile dysfunction and testosterone studies.

 

Urology Group of New Mexico clinical research profile

For more information about Urology Group of New Mexico, please visit CenterWatch.

 

The following is a list of the organizations we have worked with:

  • SWOG
  • SmithKline Beecham
  • Pfizer
  • TAP
  • Bioclinical Partners
  • Roche/Boehringer Mannheim
  • Sepracor
  • IBAH
  • Atrix
  • Bristol-Meyers Squibb
  • ILEX
  • Assert
  • Auxilium
  • Novartis
  • ALZA
  • Seattle Genetics
  • Pharmacia
  • Kendle
  • GTx, Inc.
  • Bayer
  • Merck
  • Diagnostic Oncology
  • Therion Biologics
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Watson Laboratories
  • Indevus
  • Amgen
  • Ferring
  • Astellas
  • Aerterna Zentaris
  • Nymox Pharmaceutical Corp.
  • Vantia Plarmaceuticals
  • Active Biotech
  • Takeda

Below is an overview of clinical trials experience for Urology Group of New Mexico.

  • Carbenicillin Prostatitis Study – Veteran’s Administration Hospital Clinic

Patients screened: : 20
Patients enrolled: 10
Patients completed: 5
Enrollment period: 12 months

  • Bladder Cancer, BCG Intravesical Immunotherapy Study –  SWOG

Patients screened: : 10
Patients enrolled:3
Patients completed: 3
Enrollment period: 12 months

  • Balloon Dilatation of Prostate Safety and Efficacy Study

Patients screened: 15
Patients enrolled: 10
Patients completed: 10
Enrollment period: 12 months

  • Benign Prostatic Hypertrophy Study – SmithKline Ileecham, Epristeride Study

Patients screened: : 58
Patients enrolled: 18
Patients completed: 12
Enrollment period: 3 months

  • Quinalone Prostatitis Efficacy Study – Pfrzer Pharmaceuticals, Inc.

Patients screened: : 12
Patients enrolled: 4
Patients completed: 4
Enrollment period: 4 months

  • Apomorphine SL Impotence Study, Efficacy and Complications – TAP Pharmaceuticals, Inc.

Patients screened: : 35
Patients enrolled: 14
Patients completed: 13
Enrollment period: 3 rnonths

  • Prostate Cancer PSA Study – Bioclinical Partners

Patients screened: : 15
Patients enrolled: 8
Patients completed: 8
Enrollment period: 7 months

  • Prostate Cancer PSA Device Study – Diagnostic Oncology CRO, Roche/Boehringer-Mannheim

Patients screened: : 60
Patients enrolled: 44
Patients completed: 38
Enrollment period: 4 months

  • Urinary Incontinence Study – Safety and Efficacy, IBAH, Sepracor

Patients screened: : 23
Patients enrolled: 15
Patients completed: 11
Enrollment period: 4 months

  • Prostate Cancer Hormonal Treatment Study- 9904 Phoenix International, Atrix

Patients screened: : 13
Patients enrolled: 10
Patients completed: 10
Enrollment period: 5 months

  • Prostatitis Study – Bristol-Myers Squibb

Patients screened: : 34
Patients enrolled: 4
Patients completed: 10

  • Bladder Cancer Study – ILEX

Patients screened: : 24
Patients enrolled: 1
Patients completed: 1

  • Testosterone Study – Androgel, Assert

Patients screened: : 9
Patients enrolled: 9
Patients completed: 9
Enrollment period: 4 months

  • Prostate Cancer Hormonal Treatment Study – Atrix AGL0001

Patients screened: : 6
Patients enrolled: 6
Patients completed: 6

  • Testosterone Gel Study – Auxilium 202 and 203 (extension)

Patients screened: 44
Patients enrolled: 7
Patients completed: 0
Enrollment period: 6 months

  • Testicular Prosthesis Study – Mentor

Patients screened: 6
Patients enrolled: 6
Patients completed: 1 year follow-up continues

  • PSA and DNA Sampling Prostate and Renal Cancer – Genomics

Patients screened: 44
Patients enrolled: 44
Patients completed: 44

  • Overactive Bladder – B & B Clinical Innovations Tempo

Patients screened: 2
Patients enrolled: 2
Patients completed: 2
Enrollment period: 3 months

  • Benign Prostatic Hypertrophy – Pfizer Pharmaceuticals, Inc.

Patients screened: 13
Patients enrolled: 7
Patients completed:7
Enrollment period: 4 months

  • Urgency Incontinence Study – Pfizer Pharmaceuticals, Inc.

Patients screened: 14
Patients enrolled: 10
Patients completed: 6
Enrollment period: 5 months

  • Urgency Incontinence Study Extension Phase – Pfizer Pharmaceuticals, Inc.

Patients enrolled: 6
Patients screened: Study currently active

  • Prostate Cancer Study Efficacy and Safety – Atrix AGL0205

Patients screened: 3
Patients enrolled: 3
Patients completed:  Study currently active

  • Prostate Cancer Study Bone Mineral Density – LY Zometa Novartis Pharmaceuticals, Inc.

Patients screened: 4
Patients enrolled: 4
Patients completed: still active

  • Females with Lower Urinary Tract Symptoms – Boehringer-Ingelheim Pharmaceutical, Inc. 527.25
  • Overactive Bladder Study – FesoterodineSchwarz Biosciences, Inc.
  • Overactive Bladder Study – DarifenacinPfi zerllrlovarti s Al 37 1 0 422003
  • Erectile Dysfunction – Eli Lilly Tadalafil, 2003 -2004
  • Genital Herpes – Novartis Famvir CFAM 810, 2003
  • Prostate Cancer Prevention – VioxxMerck ViP 201, 2004
  • Women with stress Incontinence- Duloxetine Eli Lilly FIJ-US-SBCD, 2004-2005
  • Males with Acute Urinary Retention – Boehringer-lngleheim 527.26 Flomax, 2003-2004
  • Males with Rapid Ejaculation – ALZA 3 studies- 013,014,04 Dapoxetine
  • Prevention of bone fractures in men with prostate cancer and on I-HRH therapy, Toremifene GTx – G3002032004-2005
  • Men with Erectile DysfunctionVardenafilGlaxoSmithKline- 2 studies, 021 and 108, 2004
  • Men with Prostate Cancer in need of first line hormonaltherapySiCor GS-121-01, 2004
  • Men with Hormone Refractory Prostate Cancer with Metastatic Disease – Vaccine Study through Therion, 2004-2005
  • Retrospective Study – Bone Metastases National Estimation of Clinical Assessment
  • Resource Evaluation among Prostate Cancer Patients- Novartis, 2004
  • Complicated Urinary Tract Infections – Cipro XL for use in Pseudomonas Patients – Bayer 11490, 2004-2005
  • A study of Toremifene Citrate for the prevention of bone fractures in men with Prostate Cancer on Androgen Deprivation Therapy – GTx, Inc.,2004-2006
  • Men with Rapid Ejaculation Dapoxetine Withdrawal study for depression – Johnson and Johnson PRE 3002, 2004-2005
  • A protocol for blood and urine sample collection from patients undergoing Prostate Biopsies who do not have previously diagnosed with Prostate Cancer. Study is to aid in the Evaluation of in-Vitro Diagnostic Devices, 2004-2005
  • A Prostate Cancer Prevention Trial for Men who have been diagnosed with High Grade Prostatic Intraepithelial Neoplasia – GTx Inc., 2005-2006
  • A protocol for Men with voiding signs and symptoms of Benign Prostatic Hypertrophy – Watson Labs, 2005
  • Open-Label Expanded Access Program (EAP) Study of 10 mg Atrasentan in Men with Metastatic Hormone-Refractory Prostate Cancer – Abbott Laboratories, 2005
  • A Double-Blind Multi-Center Randomized Placebo – Controlled Study of Safety and Efficacy of Trospim Chloride vs. Placebo for 12 weeks followed by a 9 month Open-Label treatment phase in patients with overactive bladder – Indevus Pharmaceuticals
  • A study to evaluate the clinical efficacy and safety of Tolterodine ER 4 mg in men who have frequency and urgency with or without urinary urge incontinence, with or without bladder outlet obstruction- Pfrzer, 2005
  • A study to evaluate the efficacy and safety of oxybutynin topical gel for the symptoms of Overactive Bladder – Watson Labs, 2006
  • A Phase 3 study of Denosumab on Prolonging Bone Metastasis-Free Survival in men with Hormone-Refractory Prostate Cancer – Amgen,2006
  • A study of Denosumab compared with Zoledronic Acid (Zometa) in the treatment of Bone Metastases in men with Hormone-Refractory Prostate Cancer – Amgen, 2006
  • A study assessing the efficacy and safety of Dutasteride in extending the time to progression of Low-Risk, localized Prostate Cancer in men who are candidates for or undergoing expectant management – Glaxo Smith Kline Group, 2006
  • A study comparing the efficacy of Levofloxacin at a different dose levels for different time periods in the treatment of chronic prostatitis – Advanced Biologics, 2006
  • A study using intermittent IM dosage regimens of Cetrorelix in patients with symptomatic BPHAeterna – Zenlaris, 2006
  • A study for OAB comparing Fesoterodine to Tolterodine and placebo – Pfrzer, 2007
  • A study for patients with noninvasive bladder cancerusing single dose of EOquin intravesically post surgery- Spectrum, 2007
  • A study investigating the efficacy and safety of a fast dissolving (MELT) formulation of Desmopressin for the treatment of Nocturia – Fening, 2007
  • A study using AMG386 or placebo in conjunction with Sorifenib for metastatic renal cell carcinoma
  • Three studies assessing the safety and efficacy of Beta-3 Agonist YMl78 for symptoms of overactive bladder – Astellas Pharma Europe B.V., 2008
  • A study to assess the effects of Pomegranate Extract on rising PSA levels following therapy for prostate cancer – Roll International Corp., 2008
  • A study to assess the efficacy of ABR-215050 placebo-controlled in asymptomatic patients with metastatic castrate resistant prostate cancer – Active Biotech Research, 2008
  • A study to assess Silodosinplacebo-controlled in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome – Waston Laboratories, Inc.,  2008
  • A study to assess the safety and efficacy of LibiGel® placebo-controlled for the treatment of hypoactive sexual desire disorder in surgically menopausal women – BioSante Pharmaceutical, Inc., 2008
  • A study to assess the safety and efficacy of Deforolimur in patients with metastatic prostate cancer – Merck, 2009
  • A study to assess safety and efficacy of combining tadalafil with alpha blockers for patients with BPH symptoms – Eli Lilly, 2008
  • Two studies assessing Degarelix in men with prostate cancer comparative study to Leuprilide or Goseralin – Ferring, 2009
  • Phase 3 Multicenter Prospective Randomized Parallel, group placebo controlled double blind clinical evaluation of XX-XXXX for the treatment of BPH, 2010
  • A Mulitcenter Randomized Double-Blind Placebo and Allopurinol Controlled Phase
  • 2 studies to evaluate XXX in Medical Management of Sr-objects with Hyperuricosuria and Calcium Oxalate Stones, 2010
  • A Phase 3 Randomized Double-Blind Placebo-Controlled, Multi-Center study of the Long-Term safety and efficacy of XXX for the treatment of hypoactive sexual desire disorder in postmenopausal women, 2010
  • A randomized parallel armopen-label trial comparing XXX with XXX plus antiandrogen flare protection in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk who require neoadjuvant hormone therapy prior to radiotherapy (curative intent), 2010
  • Phase II open label dose-finding study of the effect of XXX on total and free testosterone levels in men with prostate cancer compared to a luteinizing hormone releasing hormone – Agonist, 2011
  • Phase 2 multicenter prospective open label clinical safety evaluation of re-injection of XXX for the treatment of BPH: Two doses 1-7 years apart – Nyrnox, 2012
  • Retrospective follow-up for overall survival in the clinical study; Phase 2 randomized double blind placebo-controlled study to determine the efficacy of XXX in asymptomatic patients with metastatic castrate-resistant prostate cancer – Active Biotech, 2012
  • A self-selection study for the consideration of tamsulosin hydrochloride 0.4 mg in an all comers’s population of adults with bothersome urinary symptoms followed by urological assessment of selected predefined subpopulations – Boeheringer Ingelheim, 2012
  • Phase 2 multicenter prospective open label 2-dose level clinical safety and efficacy evaluation of injection of XXX for the treatment of low risk localized (Tlc) prostate cancer – Nymox, 2012